immunotherapy resistance

A Stromal CTHRC1 Biomarker Framework May Identify Colorectal Cancers With Poor Prognosis and Limited Immunotherapy Benefit

By MedXY 05/10/2026

A large multiomic colorectal cancer study identifies CTHRC1-positive fibroblasts as a stromal biomarker linked to TGF-beta activity, adverse outcomes, and reduced checkpoint inhibitor benefit across both MSI and MSS disease.

Hematology-Oncology news Oncology

When Targeting Becomes a Double-Edged Sword: How Loss of GPRC5D May Fuel Multiple Myeloma Progression

By MedXY 04/12/2026

Researchers discovered that loss of GPRC5D, a key immunotherapy target in multiple myeloma, not only confers resistance to targeted therapies but actively promotes cancer cell proliferation and competitive fitness—creating a therapeutic paradox that warrants careful clinical monitoring.

news Oncology Urology

AHR Inhibition with IK-175: A New Frontier in Overcoming Checkpoint Resistance in Urothelial Carcinoma

By MedXY 01/11/2026

This Phase 1/1b study demonstrates that IK-175, an oral AHR inhibitor, is safe and clinically active in PD-1-refractory urothelial carcinoma, showing target engagement and preliminary efficacy both as monotherapy and in combination with nivolumab.

Clinical Updates news Oncology Specialties

Overcoming PD-1 Inhibitor Resistance: Six Emerging Strategies from the 2025 ASCO Annual Meeting

By MedXY 08/06/2025

PD-1 inhibitor resistance is a major hurdle in cancer immunotherapy. Six leading combination strategies—including chemotherapy, anti-angiogenic agents, radiotherapy, novel checkpoint inhibitors, microbiome modulation, and ADCs—offer new hope for overcoming resistance and improving patient outcomes.